Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29    OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Haftungsausschluss: Dieser Artikel wurde aus anderen Medien reproduziert. Der Zweck des Nachdrucks besteht darin, mehr Informationen zu vermitteln. Dies bedeutet nicht, dass diese Website ihren Ansichten zustimmt und für ihre Authentizität verantwortlich ist und keine rechtliche Verantwortung trägt. Alle Ressourcen auf dieser Website werden im Internet gesammelt. Der Zweck des Teilens dient nur dem Lernen und Nachschlagen aller. Wenn eine Verletzung des Urheberrechts oder des geistigen Eigentums vorliegt, hinterlassen Sie uns bitte eine Nachricht.

Neueste

  • CBOF held first global Economic Summit

    ​A few days ago, the first CBOF global economic summit in Singapore in 2020 officially opened. Jun Hasegawa, CEO of CBOF Foundation, said at the CBOF Global Economic Summit that CBOF is promoting the development of the global blockchain industry through policies, including the cultivation of blockchain talents, the technological advantages of CBOF, the prospect of fintech, the future development p
  • How does OMEX, the king of contracts, stand out and create a new experience in contract trading

    ​As an indispensable link in the digital asset industry chain, the exchange undertakes important tasks such as asset management, matching transactions, and asset clearing. It is the core link connecting the upstream and downstream of the digital asset industry chain. The exchange not only releases the value of digital assets, but also allows this value to be effectively integrated with the current
  • Förderung von Investitionen in Forschung und Entwicklung: 100.000-€-Spende der kENUP Foundation an den COVID-19 R&D Fund in Malta

    VALLETTA, Malta--Die kENUP Foundation hat eine Spende von 100.000 Euro an den maltesischen COVID-19 R&D Fund überreicht. Der Fonds wird gemeinsam vom Malta Council for Science and Technology (MCST) und Malta Enterprise mit Unterstützung des Ministeriums für Finanzen und Finanzdienstleistungen sowie des Ministeriums für Wirtschaft, Investitionen und Kleinunternehmen verwaltet. Über den Malta-Fonds
  • Imricor kündigt erste Vertriebskooperation mit Philips an

    MINNEAPOLIS---Imricor Medical Systems, Inc. (Unternehmen oder Imricor) (ASX:IMR) der weltweite Marktführer für MRI-gestützte Produkte für kardiale Ablation, freut sich, die erste Vertriebskooperation mit einem der globalen Marktführer im Bereich Gesundheitstechnik, ankündigen zu dürfen.
  • YellowScan-Kartierungssysteme der neuesten Generation verlassen sich auf Velodyne-Lidar-Sensoren, um anspruchsvolle Anforderungen von Vermessungsfachleuten zu erfüllen

    AN JOSE, Kalifornien---Velodyne Lidar, Inc. gab heute bekannt, dass zwei mobile YellowScan-Kartensysteme der neuen Generation die Lidar-Sensoren von Velodyne verwenden, um die hohe Präzision und Genauigkeit zu erreichen, die für die 3D-Kartierung aus der Luft erforderlich ist. Die leistungsstarken Velodyne-Lidar-Sensoren erzeugen georeferenzierte Point-Cloud-Daten in Echtzeit, mit denen YellowScan
  • The three-in-one Tinanik sunscreen innovates sun-proof, whitening and anti-aging

    As everyone knows, sunscreen has a very important position in the skin-care industry. It can not only prevent sunburn, but also play an important role in reducing the incidence rate of skin cancer. With the improvement of people’ s requirements for sunscreen, single sunscreen efficacy can not meet the needs of consumers. Nowadays, women proposed new requirements, like refuse sunburn, whitening and
  • Bayer and OrigiMed reached a partnership on CDx-IVD development

    Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor appr
  • Zum 5. Jahrestag richtet Teckro den Blick in die Zukunft und erweitert Führungsteam zur Beschleunigung seines Wachstums

    Am fünften Jahrestag seiner Gründung erweitert Teckro sein Führungsteam, um der wachsenden Nachfrage im Zusammenhang mit COVID-19 gerecht zu werden.
  • Mr. Lip-Bu Tan, Chairman of Walden International, On the 20th Anniversary of SMIC & Its IPO in the STAR Market

    Semiconductor Manufacturing International Corporation (“SMIC”) went public on the Sci-Tech Innovation Board (STAR Market) on 16 July. It took only 19 days for SMIC to gain regulatory approval, breaking the record for the STAR Market. The over-allotment option was fully exercised, thus raising a total of 53.2 billion yuan. Based on the issue price, SMIC’s market value will reach a record-setting 2
  • Newchic Summer Sale 2020 Promotion Is On Now

    Up to 90% OFF Sale! The affordable fashion shopping site -- Newchic Summer Sale 2020 is coming! Buy 2 get 1 free, free shipping snap up and join their lucky draw activity to win free shipping coupon for a whole year! Newchic Summer Sale 2020 kicked off Monday, 6th July, and will run until Monday, 27th July, ending at 9 a.m UTC. Besides, you can earn up to 50% commissions by participating in their

Link

Back to top
© Copyright 2006-2020 autodaily.de      Kontaktieren Sie Uns   SiteMap